샘플 요청 목록

 카트 문의
시장보고서
상품코드
1419009

유럽의 구속성 펩타이드 의약품 시장 - 분석 및 예측(2024-2040년)

Europe Constrained Peptide Drugs Market: Analysis and Forecast, 2024-2040
발행일: | 리서치사: BIS Research | 페이지 정보: 영문 | 배송안내 : 1-5일 (영업일 기준)

    
    
    




■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.

주요 시장 통계
예측 기간 2026년-2040년
2026년 평가 6,000만 달러
2040년 전망 77억 2,000만 달러
CAGR 41.55%

유럽의 구속성 펩타이드 의약품 시장 규모는 2026년 6,000만 달러, 2040년 77억 2,000만 달러에 달할 것으로 예상되며, 예측 기간인 2026-2040년 CAGR은 41.55%를 나타낼 것으로 예상됩니다.

제약 펩타이드 약물 시장은 이제 단순한 수용체 이상의 것을 표적으로 삼는 혁신적인 제약 펩타이드 파이프라인에 힘입어 큰 성장을 보일 것으로 예상됩니다. 화학 기술의 발전, 합성 펩타이드의 치료 성공, 다양한 질병에 대한 접근성 또한 예측 기간 동안 예측된 성장에 기여하고 있습니다.

유럽의 구속성 펩타이드 의약품 시장은 향후 몇 년동안 크게 성장할 것으로 예상됩니다. 이러한 시장 확대의 주요 원동력 중 하나는 R&D, 혁신, 강력한 규제 프레임워크를 특징으로 하는 이 지역의 탄탄한 제약 산업입니다. 유럽 제약사들은 펩타이드 화학의 첨단 기술과 전문 지식을 활용하여 구속성 펩타이드 의약품 개발에서 선두를 달리고 있습니다.

또한, 유럽에서는 특히 암, 자가면역질환, 대사성 질환 등 다양한 질환의 치료에서 새로운 치료 접근법에 대한 수요가 증가하고 있습니다. 구속성 펩타이드는 특이성, 효능과 안전성을 향상시킬 수 있는 가능성으로 인해 유망한 해결책을 제시합니다.

또한, 유럽에서는 학회, 연구기관, 제약사 간의 공동 노력으로 구속성 펩타이드 기반 치료제의 발견과 개발이 가속화되고 있습니다. 이러한 협력적 생태계는 혁신을 촉진하고 유럽을 구속성 펩타이드 의약품 시장에서 중요한 진입 시장으로 자리매김하고 있습니다.

이 보고서는 유럽의 구속성 펩타이드 의약품 시장에 대해 조사했으며, 시장 개요와 함께 국가별, 기업별 동향, 시장 진출기업 프로파일 등을 전해드립니다.

목차

주요 요약

제1장 정의

제2장 조사 범위

제3장 조사 방법

제4장 시장 개요

  • 서론
    • 구속성 펩티드 구조와 설계
    • 구속성 펩티드 유형
  • 성장 억제요인 된 펩티드 진화
  • 약제로서의 구속성 펩티드 개발
  • 잠재적인 치료 영역
  • 밸류체인 - 주요 이해관계자
  • 주요 업계 동향(지역별)
  • 행정 경로별 주요 업계 동향
  • 주요 업계 동향 -기술 발전
  • 현재 시장 규모와 성장 가능성, 10억 달러, 2024년-2040년
  • COVID-19가 구속성 펩타이드 의약품 시장에 미치는 영향
    • 구속성 펩타이드 의약품의 기업에 대한 영향
    • 임상시험 중단과 재개

제5장 유럽

  • 구속성 펩타이드 의약품 시장(국가별), 10억 달러, 2024년-2031년
    • 유럽

제6장 기업 개요

  • Bicycle Therapeutics plc
  • Spexis AG
  • Santhera Pharmaceuticals
  • Union Chimique Belge S.A.(UCB)
  • Biosynth(Pepscan)
LSH 24.02.07

“The Europe Constrained Peptide Drugs Market Expected to Reach $7.72 Billion by 2040.”

Introduction to Europe constrained peptide drugs market

KEY MARKET STATISTICS
Forecast Period2026 - 2040
2026 Evaluation$0.06 Billion
2040 Forecast$7.72 Billion
CAGR41.55%

The market size is anticipated to be $0.06 billion in 2026 and is expected to reach $7.72 billion by 2040, growing at a CAGR of 41.55% during the forecast period 2026-2040. The constrained peptide drugs market is expected to experience significant growth, driven by innovative constrained peptide pipelines that now target more than just receptors. Advances in chemical technologies, the success of synthetic peptides in therapeutics, and their affordability across various diseases are also contributing to the projected growth in the forecast period.

Market Introduction

The Europe constrained peptide drugs market is poised for substantial growth in the coming years. One of the key drivers of this expansion is the region's robust pharmaceutical industry, characterized by a focus on research and development, innovation, and a strong regulatory framework. European pharmaceutical companies have been at the forefront of developing constrained peptide drugs, leveraging cutting-edge technologies and expertise in peptide chemistry.

Additionally, Europe has witnessed a growing demand for novel therapeutic approaches, particularly in the treatment of various diseases such as cancer, autoimmune disorders, and metabolic conditions. Constrained peptides offer a promising solution due to their specificity and potential for enhanced efficacy and safety profiles.

Furthermore, collaborative efforts between academia, research institutions, and pharmaceutical companies in Europe have accelerated the discovery and development of constrained peptide-based therapeutics. This collaborative ecosystem fosters innovation and positions Europe as a significant player in the constrained peptide drugs market.

Market Segmentation

Segmentation 1: by Country

  • Germany
  • U.K.
  • France
  • Italy
  • Spain

Segmentation 2: by Company

  • Bicycle Therapeutics plc
  • Spexis AG
  • Santhera Pharmaceuticals
  • Union Chimique Belge S.A. (UCB)
  • Biosynth (Pepscan)
  • Zealand Pharma

How can this report add value to an organization?

Workflow/Innovation Strategy: Over the past decade, peptide drug discovery and development has witnessed a renaissance and scientific thrust as the industry has come to acknowledge the capability of peptide therapeutics in addressing unmet medical needs and the potential of this class of molecules to become a significant accompaniment or even favored alternative treatment to biologics and small molecules.

Peptide therapeutics have demonstrated a novel and selective yet safe mode of action for a wide range of indications. The existing and future development of constrained peptide drugs will continue to burgeon upon the strengths of constrained peptides and innovative technologies employed in the discovery and development, including peptide drug conjugates, multifunctional peptides, and cell-penetrating peptides. Furthermore, limitations associated with presently available peptides have resulted in an urgent need for new design, administration, and synthesis in peptide therapeutics, thereby leading to advancements in the development of constrained peptides.

Growth/Marketing Strategy: Constrained peptides provide noteworthy advantages over linear peptides. An increase in interest in constrained peptides due to their properties led to advancements in peptide synthesis technologies.

Competitive Strategy: Key players in the Europe constrained peptide drugs market have been analyzed and profiled in the study, including manufacturers involved in new product development, acquisitions, expansions, and strategic collaborations. Moreover, a detailed competitive benchmarking of the players operating in the Europe constrained peptide drugs market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Table of Contents

Executive Summary

1. Definition

  • 1.1. Inclusion and Exclusion Criteria

2. Research Scope

  • 2.1. Key Questions Answered in the Report

3. Research Methodology

  • 3.1. Constrained Peptides: Research Methodology
  • 3.2. Primary Data Sources
  • 3.3. Secondary Data Sources
  • 3.4. Market Estimation Model
  • 3.5. Criteria for Company Profiling

4. Markets Overview

  • 4.1. Introduction
    • 4.1.1. Structure and Design of Constrained Peptides
    • 4.1.2. Types of Constrained Peptides
  • 4.2. Evolution of Constrained Peptides
  • 4.3. Development of Constrained Peptides as Drugs
  • 4.4. Potential Therapy Areas
  • 4.5. Value Chain-Key Stakeholders
  • 4.6. Key Industry Trends (by Region)
  • 4.7. Key Industry Trends by Route of Administration
  • 4.8. Key Industry Trends-Technological Advancements
  • 4.9. Current Market Size and Growth Potential, $Billion, 2024-2040
  • 4.1. COVID-19 Impact on Constrained Peptides Drugs Market
    • 4.10.1. Impact on Constrained Peptide Drugs Companies
    • 4.10.2. Clinical Trial Disruptions and Resumptions

5. Europe

  • 5.1. Constrained Peptide Drugs Market (by Country), $Billion, 2024-2031
    • 5.1.1. Europe
      • 5.1.1.1. U.K.
      • 5.1.1.2. Germany
      • 5.1.1.3. France
      • 5.1.1.4. Italy
      • 5.1.1.5. Spain

6. Company Profiles

  • 6.1. Overview
  • 6.2. Bicycle Therapeutics plc
    • 6.2.1. Company Overview
    • 6.2.2. Role of Bicycle Therapeutics plc in the Constrained Peptide Drugs Market
    • 6.2.1. Current Status and Policies for Investigational Drugs
    • 6.2.2. Key Competitors of the Company
    • 6.2.3. Financials
    • 6.2.4. Key Insights about the Financial Health of the Company
    • 6.2.5. Corporate Strategies
      • 6.2.5.1. Synergistic Activities
      • 6.2.5.2. Funding
    • 6.2.6. Business Strategies
      • 6.2.6.1. Clinical Developments
      • 6.2.6.2. Regulatory and Legal
    • 6.2.7. Analyst Perspective
  • 6.3. Spexis AG
    • 6.3.1. Company Overview
    • 6.3.2. Role of Spexis AG in the Constrained Peptide Drugs Market
    • 6.3.3. Current Status and Policies for Investigational Drugs
    • 6.3.4. Key Competitors of the Company
    • 6.3.5. Financials
    • 6.3.6. Key Insights about the Financial Health of the Company
    • 6.3.7. Corporate Strategies
      • 6.3.7.1. Funding
      • 6.3.7.2. Mergers and Acquisitions
      • 6.3.7.3. Synergistic activities
    • 6.3.8. Business Strategies
      • 6.3.8.1. Regulatory and Legal
    • 6.3.9. Analyst Perspective
  • 6.4. Santhera Pharmaceuticals
    • 6.4.1. Company Overview
    • 6.4.2. Role of Santhera Pharmaceuticals in the Constrained Peptide Drugs Market
    • 6.4.3. Current Status and Policies for Investigational Drugs
    • 6.4.4. Key Competitors of the Company
    • 6.4.5. Financials
    • 6.4.6. Corporate Strategies
      • 6.4.6.1. Funding
    • 6.4.7. Business Strategies
      • 6.4.7.1. Clinical Developments
    • 6.4.8. Analyst Perspective
  • 6.5. Union Chimique Belge S.A. (UCB)
    • 6.5.1. Company Overview
    • 6.5.2. Role of Union Chimique Belge S.A. (UCB) in the Constrained Peptide Drugs Market
    • 6.5.3. Current Status and Policies for Investigational Drugs
    • 6.5.4. Key Competitors of the Company
    • 6.5.5. Financials
    • 6.5.6. Key Insights about the Financial Health of the Company
    • 6.5.7. Corporate Strategies
      • 6.5.7.1. Mergers and Acquisitions
    • 6.5.8. Business Strategies
      • 6.5.8.1. Clinical Developments
      • 6.5.8.2. Regulatory and legal
    • 6.5.9. Analyst Perspective
  • 6.6. Biosynth (Pepscan)
    • 6.6.1. Company Overview
    • 6.6.2. Role of Biosynth (Pepscan) in the Constrained Peptide Drugs Market
    • 6.6.3. Key Competitors of the Company
    • 6.6.4. Corporate Strategies
      • 6.6.4.1. License
    • 6.6.5. Business Strategies
      • 6.6.5.1. Product Launch
    • 6.6.6. Analyst Perspective
    • 6.6.7. Zealand Pharma
      • 6.6.7.1. ZP10000 (Preclinical)
        • 6.6.7.1.1. Product Profile
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제